Fatigue

CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A

Monday, September 27, 2021 - 5:30pm

This is a livestream presentation, and a link will also be posted on CytoDyns website approximately 48 hours after the presentation.

Key Points: 
  • This is a livestream presentation, and a link will also be posted on CytoDyns website approximately 48 hours after the presentation.
  • The conference sponsor provides corporate visibility services to CytoDyn for a fee.
  • It binds to CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.
  • Leronlimab does not work on other strains of HIV (for example X4), however, R5 is the most dominant strain of HIV.

Energy, Focus, Intention: New CBD Strength Gummy from House of Wise Empowers Women to Reclaim Their Workout Routines, Make the Most of Time Spent in Motion

Monday, September 27, 2021 - 3:32pm

MIAMI, Sept. 27, 2021 /PRNewswire/ -- Today, CBD and personal wellness brand House of Wise announces a new vertical in its line of vegan CBD products: Strength .

Key Points: 
  • MIAMI, Sept. 27, 2021 /PRNewswire/ -- Today, CBD and personal wellness brand House of Wise announces a new vertical in its line of vegan CBD products: Strength .
  • "House of Wise makes products that help me optimize the way I feel at work, at rest, and now at the gym.
  • House of Wise empowers women to take control of their lives while working to shatter the stigmas and double standards women face today.
  • She is a leader and advocate breaking down stigmas and stereotypes surrounding CBD, cannabis, and the role of women in our society today.

Ambow Education Awarded Another U.S. Patent

Monday, September 27, 2021 - 1:30pm

BEIJING, Sept. 27, 2021 /PRNewswire/ --Ambow Education Holding Ltd. ("Ambow" or the "Company") (NYSE American: AMBO), a leading cross-border career educational and technology service provider, today announced that the United States Patent and Trademark Office has granted the Company an International Patent for "Method and Device for Adaptively Controlling Multimedia Blackboard, Medium and Electronic Apparatus" (Patent Number: US011017565B1).

Key Points: 
  • BEIJING, Sept. 27, 2021 /PRNewswire/ --Ambow Education Holding Ltd. ("Ambow" or the "Company") (NYSE American: AMBO), a leading cross-border career educational and technology service provider, today announced that the United States Patent and Trademark Office has granted the Company an International Patent for "Method and Device for Adaptively Controlling Multimedia Blackboard, Medium and Electronic Apparatus" (Patent Number: US011017565B1).
  • Dr. Jin Huang, President and Chief Executive Officer of Ambow, commented, "Being awarded another U.S. patent is a powerful testament to our new technology's leadership worldwide.
  • It also illustrates the significant progress we have made in international intellectual property protection and the layout of our patent portfolios.
  • About Ambow Education Holding Ltd.
    Ambow Education Holding Ltd. is a leadingcross-border careereducational andtechnology service provider, offering high-quality, individualized services and products.

Harvest One Announces Warrants Issued for Consulting Services

Monday, September 27, 2021 - 12:45pm

Vancouver, British Columbia--(Newsfile Corp. - September 27, 2021) - Harvest One Cannabis Inc. (TSXV: HVT) (OTCQB: HRVOF) ("Harvest One" or the "Company"), a uniquely positioned cannabis-infused and non-infused consumer packaged goods ("CPG") leader, announces that further to the press release of the Company dated July 26, 2021, relating to the strategic advisory and consulting services to the Company (the "Consulting Services") to be provided by an arm's length service provider, Jonathan Carroll (the "Consultant"), the Company has issued 300,000 warrants (the "Warrants") to the Consultant pursuant to the terms of the consulting agreement entered into relating to the Consulting Services (the "Consulting Agreement").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - September 27, 2021) - Harvest One Cannabis Inc. (TSXV: HVT) (OTCQB: HRVOF) ("Harvest One" or the "Company"), a uniquely positioned cannabis-infused and non-infused consumer packaged goods ("CPG") leader, announces that further to the press release of the Company dated July 26, 2021, relating to the strategic advisory and consulting services to the Company (the "Consulting Services") to be provided by an arm's length service provider, Jonathan Carroll (the "Consultant"), the Company has issued 300,000 warrants (the "Warrants") to the Consultant pursuant to the terms of the consulting agreement entered into relating to the Consulting Services (the "Consulting Agreement").
  • Based on the terms of the Consulting Agreement, the exercise price of each Warrant is $0.089.
  • The Warrants and the Common Shares issuable on exercise of the Warrants are subject to a hold period until January 25, 2022, in accordance with applicable securities laws.
  • Harvest One is a uniquely positioned company in the cannabis space which is commercializing both cannabis-infused and non-infused products.

Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases

Monday, September 27, 2021 - 11:00am

"Incyte is a proven leader in the development and commercialization of many important innovative therapies, including a treatment for GVHD.

Key Points: 
  • "Incyte is a proven leader in the development and commercialization of many important innovative therapies, including a treatment for GVHD.
  • Syndax and Incyte are seeking to develop axatilimab as a backbone therapy for patients with cGVHD as well as in additional immune-mediated diseases where CSF-1R-dependent monocytes and macrophages are believed to contribute to organ fibrosis.
  • Enrollment continues in the ongoing global pivotal Phase 2 AGAVE-201 trial of axatilimab monotherapy in patients with cGVHD, with topline data expected in 2023.
  • Under the terms of the agreement, Incyte will lead global commercial activities for axatilimab across all indications.

Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 against COVID-19

Friday, September 24, 2021 - 3:58pm

Inhaled PUL-042 stimulates the lungs innate immune system with the potential to protect against a wide variety of respiratory pathogens.

Key Points: 
  • Inhaled PUL-042 stimulates the lungs innate immune system with the potential to protect against a wide variety of respiratory pathogens.
  • PUL-042 could be directed against all existing and future variants of the SARS-CoV-2 virus, as well as future pandemics.
  • Based on the promising results from this trial and remarkable activity in pre-clinical models, PUL-042 also has potential for use in other patient populations.
  • The median time to improvement of respiratory symptoms was 6 days for PUL-042 and 9 days for placebo.

Nurse.org Launches Social Media Campaign Revealing Causes of #TheREALNursingShortage

Friday, September 24, 2021 - 11:00am

"We are overworked, underpaid, and are collectively feeling the effects of burnout, compassion fatigue, and moral injury."

Key Points: 
  • "We are overworked, underpaid, and are collectively feeling the effects of burnout, compassion fatigue, and moral injury."
  • As part of the campaign, nurses are encouraged to:
    Sign a pledge of support to amplify the systemic issues causing nurses to leave and advocate for true change within the nursing profession.
  • Share a photo or video on social media to amplify the REAL issues influencing the nursing shortage using hashtag #TheREALNursingShortage.
  • Nurses interested in supporting the campaign can visit Nurse.org and follow the social media accounts on Instagram and Facebook.

Long-Term CRYSVITA® ▼ (burosumab) Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia (XLH), a Rare Genetic Metabolic Bone Disease

Friday, September 24, 2021 - 9:00am

Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) today announced the publication of new data highlighting the sustained benefits of treatment with CRYSVITA (burosumab) in adults with X-linked hypophosphataemia (XLH), a rare genetic metabolic bone disease.

Key Points: 
  • Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) today announced the publication of new data highlighting the sustained benefits of treatment with CRYSVITA (burosumab) in adults with X-linked hypophosphataemia (XLH), a rare genetic metabolic bone disease.
  • The data show that adults with XLH experience substantial pain, stiffness, fatigue and impairment in physical and ambulatory function.
  • Burosumab treatment has previously been shown to improve phosphate homeostasis in adult XLH patients, compared to placebo.
  • One of our areas of focus is to generate new data that improve our understanding of how best to manage and treat XLH.

Topical Magnesium is the Best Way to Get the Essential Mineral to Keep Your Body in Optimal Condition

Thursday, September 23, 2021 - 7:32pm

Beyond the enjoyment factor, topical application of magnesium is the best way to increase cellular magnesium levels.

Key Points: 
  • Beyond the enjoyment factor, topical application of magnesium is the best way to increase cellular magnesium levels.
  • The best way to get magnesium into your body is with topical application of quality magnesium oils, gels,and bath crystals.
  • Magnesium Gel: Less concentrated, Magnesium Gel provides the benefits of purified magnesium chloride formulated with seaweed extract for people with more sensitive skin.
  • We want them to know that topical magnesium application is the best way to meet theirnecessary magnesium requirements.

Honeywell Introduces New Robotic Technology To Help Warehouses Boost Productivity, Reduce Injuries

Thursday, September 23, 2021 - 2:17pm

CHARLOTTE, N.C., Sept. 23, 2021 /PRNewswire/ -- Honeywell (Nasdaq: HON) announced today its latest innovation in robotic technology designed to help warehouses and distribution centers automate the manual process of unloading pallets, reducing the operational risks of potential injuries and labor shortages.

Key Points: 
  • CHARLOTTE, N.C., Sept. 23, 2021 /PRNewswire/ -- Honeywell (Nasdaq: HON) announced today its latest innovation in robotic technology designed to help warehouses and distribution centers automate the manual process of unloading pallets, reducing the operational risks of potential injuries and labor shortages.
  • "Even when manual operations are running smoothly without injuries, the physical, repetitive task of unloading pallets is variable and limited by human constraints," said Dr. Thomas Evans, Chief Technology Officer of Honeywell Robotics.
  • With the labor constraints warehouses and distribution centers are seeing in filling these manual roles, this solution can be an ideal fit to help keep up with daily order volumes."
  • This technology allows for seamless handling of a continuous flow of pallets in any sequence without requiring any pre-programming or operator intervention.